ISSN: 2582-7219

International Journal of Multidisciplinary Research in Science, Engineering and Technology

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

Impact Factor: 8.206

Volume 8, Issue 10, October 2025

© 2025 IJMRSET | Volume 8, Issue 10, October 2025| DOI:10.15680/IJMRSET.2025.0810045

ISSN: 2582-7219 | www.ijmrset.com | Impact Factor: 8.206| ESTD Year: 2018|

International Journal of Multidisciplinary Research in Science, Engineering and Technology (IJMRSET)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

Pharmacotherapy for Depression and Anxiety

Mr. Ruhit Ashraf *[1]

Assistant Professor, S. Lal Singh Memorial College of Pharmacy, Desh Bhagat University, Punjab, India[1]

Ms. Hema Rani [2]

Associate Professor, S. Lal Singh Memorial College of Pharmacy, Desh Bhagat University Punjab, India[2]

Mr. Mubashir Ibni Bashir [3]

Pursuing B. Pharmacy, S. Lal Singh Memorial College of Pharmacy, Desh Bhagat University, Punjab, India[3]

ABSTRACT: The prevalence of depression and anxiety disorders is very high, and they are associated with a high rate of care utilization, a high illness burden, major economic repercussions, and a significant decline in the quality of life for patients and their families. There are several successful treatments for anxiety and depression, such as antidepressant medications and different forms of psychotherapy. Although it is uncertain if both therapeutic approaches are equally beneficial for any type of anxiety or depression, they are both being demonstrated to be effective. Antidepressant medications and psychological therapy are useful in treating depression and anxiety, but it's not apparent if they work as well for other disorders or if various forms of treatment, such psychotherapy and antidepressants, are equally effective for each disorder. Psychiatric medical care encompasses a wide range of course of action types and goals, from fully autonomous and comprehensive regimens to basic supporting or medication-compliance treatments. Research indicates that there is a complex relationship between medication and cognitive-behavioral therapy (CBT) in the treatment of depression and anxiety, and that a combination of therapies may be helpful when treating persistent depression to prevent recurrence. Drug therapy that includes a defined treatment paradigm, targets for fulfillment, complementary measures, and frequent monitoring is likely to be a suitable comparison condition for assessing whether autonomous psychological therapy adds value. Although the effects of drug therapy on quality of life have not yet been fully investigated, it is a successful treatment for diseases connected to anxiety. Anxiety and depression disorders are quite prevalent and are associated with a severe decline in the quality of life for patients and their families, a high rate of service use, high costs, and a significant burden of disease on the general population.

KEYWORDS; Depression, Antidepressants, Psychotherapies, Cognitive Behavioral Therapy

I. INTRODUCTION

According to estimates, 20.6% of American adults, or 51.5 million people, suffer from a mental disease.[1] The prevalence of any mental disorder is higher among younger adults (29.4% in years 18–24) than middle-aged people (25.0% in ages 26–49) or older persons (14.1% in ages 50 and more), and it is higher among females (24.5%) than males (16.3%).[1]. When you feel excessive tension and worry for little or no apparent reason, you may have generalized anxiety disorder. Panic disorder: You have an intense panic attack after experiencing sudden, overwhelming terror. A hammering pulse, chest pain, and excessive perspiration are all possible symptoms of an anxiety attack. You can get symptoms that According resemble fainting or a heart attack. disorder of social anxiety, Also referred to as social phobia, it happens when you experience overwhelming fear and self-consciousness during everyday social encounters. You worry that people will view you negatively. humiliated or disgraced by others.
beyond what is rational and could make you avoid everyday situations. Agoraphobia is a severe concern. fear finding themselves in a predicament where it would seem impossible to flee or seek assistance in an emergency. For example, Strong anxieties of a specific thing or situation, like cliffs or airplanes, are known as specific phobias. The fear goes you may have worry or terror when waiting, traveling by public transportation, or flying. in front of a crowd. Young children are not the only ones that suffer from separation anxiety. Separation anxiety disorder can affect anyone. Doing so will cause you to feel extremely anxious or panicked when the person closest to you leaves your line of sight. You will constantly worry about the worst possible outcome for the person you care about. One type of social anxiety is selective mutism. which young kids who talk to their families on a frequent basis avoid speaking in front of others,

© 2025 IJMRSET | Volume 8, Issue 10, October 2025| DOI:10.15680/IJMRSET.2025.0810045

ISSN: 2582-7219 | www.ijmrset.com | Impact Factor: 8.206| ESTD Year: 2018|

International Journal of Multidisciplinary Research in Science, Engineering and Technology (IJMRSET)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

including at school. Anxiety disorders brought on by medication: Using some medications or illegal drugs, as well as stopping them, might result in symptoms associated to anxiety.[2]

II. PRINCIPLES OF PHARMACOTHERAPY FOR ANXIETY

Assessment and Diagnosis

Although the US, up to 11.7% of adults report experiencing anxiety, uneasiness, or concern on a regular excessive anxiety can impair function,[3] it is thought to be a typical response to stimuli. 39 In basis. 40 Given that 45.7% of people with lifelong depression also have one or more anxiety disorders,[4] anxiety and depression frequently coexist.[5] "Persistent and excessive worry that interferes with daily activities" is the hallmark of generalized anxiety disorder (GAD), the most prevalent type of anxiety disorder. [3] As with MDD, it is recommended to employ a validated tool for screening and measurement-based care. Similar to the PHQ-9 for evaluating MDD, the GAD-7 is a quick screening tool that is based on the DSM-5's criteria for GAD symptoms.[6]

Goals of Pharmacotherapy for Generalized Anxiety Disorder

Pharmacotherapy for GAD aims to reduce symptom burden over time, just like MDD. Anxiety is more likely than depression to begin earlier in life and to be chronic or prolonged (as opposed to episodic).[7] According to one longitudinal study, the remission rates for GAD at 1, 2, and 5 years were 15%, 25%, and 38%, respectively, suggesting that remission or sustained recovery may be less frequent for anxiety than for depression.[8],[9]Similarly, compared to people with nonanxious depression, depressed patients with comorbid anxiety had a significantly lower chance of achieving remission and a higher chance of experiencing side effects or adverse events of therapy throughout the first phase of the STAR∗D research.[10] Given that their baseline symptom burden was comparatively lower than that of patients in mental health specialty settings, primary care patients with GAD may have a higher chance of seeing symptom reduction. [11]Reduction of symptom load and improvement of function are also appropriate aims of therapy, even though remission or sustained recovery is the ultimate goal of pharmacotherapy for GAD, which may be hard for some patients to achieve.

Pharmacotherapy Options and Strategies for Generalized Anxiety Disorder

For long-term management, a number of antidepressants, such as SSRIs, SNRIs, vilazodone (Viibryd), and mirtazapine (Remeron), are regarded as first-line treatments since they effectively reduce anxiety symptoms.[12] Note that the FDA has not authorized all antidepressant drugs for the treatment of anxiety disorders. The U.S. FDA has approved

ISSN: 2582-7219 | www.ijmrset.com | Impact Factor: 8.206| ESTD Year: 2018|

International Journal of Multidisciplinary Research in Science, Engineering and Technology (IJMRSET)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

venlafaxine (Effexor, Effexor XR), duloxetine (Cymbalta), paroxetine (Paxil, Paxil CR), and escitalopram (Lexapro) for the treatment of GAD. [12] Serotonergic antidepressants such as vilazodone (Viibryd), desvenlafaxine (Pristiq), citalopram (Celexa), and mirtazapine (Remeron) do not have a specific indication for any anxiety disorder; however, there is evidence that they are effective in treating anxiety when taken off-label. [13],[14] Finding proof and justification for use is a general step in the off-label prescription process. examining for any warning signs, talking with the patient about the options and justification, and recording the information, justification the results of other antidepressant classes for anxiety are quite unclear, an SSRI would be the better choice for account beginning treatment because of its expected general tolerability. 50 When choosing an agent, one should take, and patient's consent.[15]

increased energy, is a beneficial side effect of antidepressants for those with depression. Antidepressant Since into what has previously worked for the individual or their first-degree relative[14], match medicine selection to the activating patient's sickness features, and choose an agent with a good side effect profile for a particular patient. Activation, or effects, however, might manifest as restlessness or even heightened anxiety or panic in those with anxiety. Certain antidepressants have a stronger correlation with activation than others, including bupropion (Wellbutrin, Wellbutrin SR, and Wellbutrin XL), fluoxetine (Prozac),and venlafaxine (Effexor, Effexor XR) may be administered with caution to those who have had anxiety or panic in the past.[16]

It is important to titrate since people with GAD may eventually need larger dosages of antidepressants than people with MDD.[17] Clinicians should be aware that, in contrast to MDD, the initiation of antidepressant symptom improvement may be delayed in GAD, with some patients experiencing remission after six months and a response after 12 to 24 weeks [18].[19]. Additionally, medication may be ongoing because GAD has a more chronic and prolonged course than episodic MDD. Studies on relapse prevention have demonstrated a substantial advantage for patients who continue taking their medications for up to 18 months as opposed to switching to a placebo.[18] Nonetheless, it is possible to try stopping GAD medication, provided that any recurrence of symptoms is closely watched for and treated right away.

Buspirone (BuSpar), a long-acting, non-sedating, non-dependence-forming medication that lowers anxiety by 5-HT 1A partial agonism and increases dopamine and norepinephrine activity, is another medication that can be used to treat GAD. [19]. Clinical effects often appear 1-2 weeks after starting, and like SSRIs and SNRIs, buspirone can then be titrated to achieve desired results. [19]. Because of its unique mode of action, it can be used as a monotherapy for those who cannot tolerate SSRIs or SNRIs because of weight gain or adverse effects, including sexual side effects, or as an adjunct for people who only partially respond to these medications. [19], [12]

There aren't many uncontrolled possibilities for temporary anxiety alleviation. One first-generation antihistamine that can be used to treat acute anxiety symptoms is hydroxyzine (Atarax, Vistaril). [16] It has a 15–20 minute onset time and can be used as needed, either when acute anxiety starts or on a regular basis to lessen expected anxiety. [16] Regular use should be restricted to a few weeks, and long-term treatment options, like an SSRI, should be taken into consideration if symptoms continue. [16]

Use of Benzodiazepines

The FDA required an update to the Boxed Warning for benzodiazepines in September 2020 in order to reflect the "serious risks of abuse, addiction, physical dependence, and withdrawal reactions."[20] According to the revised guidelines, prescribers should carefully consider the potential advantages and disadvantages of benzodiazepines, including the risk of abuse, misuse, and addiction; limit the dosage and length of therapy to the lowest amount required;[20] and closely monitor for abuse, misuse, and addiction during treatment. The pooled data for benzodiazepines in a recent meta-analysis of anxiety therapies showed a modestly positive effect on anxiety symptoms with an effect size comparable to that of SSRIs, SNRIs, and buspirone; however, the tolerability of benzodiazepines was significantly worse than that of these medications.[21] The best use of benzodiazepines should be short-term, dose-judicious, and closely monitored for dependence or misuse during follow-up.[20][22]

© 2025 IJMRSET | Volume 8, Issue 10, October 2025| DOI:10.15680/IJMRSET.2025.0810045

ISSN: 2582-7219 | www.ijmrset.com | Impact Factor: 8.206| ESTD Year: 2018|

International Journal of Multidisciplinary Research in Science, Engineering and Technology (IJMRSET)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)



III. REFERRAL TO SPECIALTY CARE

main care physicians should be ready to treat and monitor treatment response, including making referrals to mental health specialists for medication management and counseling services when necessary, according to the USPSTF recommendation for depression screening in main care. [23]. 129 million Americans currently live in areas where there is a deficit of mental health professionals, according to the US Health Resources and Services Administration. [24] By practicing to the best of their abilities, treating patients with mild to moderate symptoms with both pharmaceutical and nonpharmacologic treatments, and saving referrals for suitable situations, primary care physicians can contribute to addressing the lack of mental health specialists.[25] Seeking advice from a mental health professional may be beneficial for patients with severe symptoms, comorbidities (such as a history of mania or hypomania), or an unusual or insufficient response to treatment.

IV. DEPRESSION

Cognitive deficits have long been the focus of intensive study attention and are commonly noticed during depressive episodes. The majority of studies have concentrated on determining which aspects of mental functioning could be compromised [26]. Particularly in medical contexts, depression is still recognized as a distinct diagnostic entity [27]. More than five symptoms that indicate a change from a previous level of functioning must exist for at least two weeks in order to identify a severe case of depressive illness. Depression, disinterest, or at least one of the symptoms must beenjoyment. (ii) Mood swings, decreased enthusiasm or enjoyment of tasks, weight loss or gain, sleeplessness or hypersomnia, psychomotor disturbances or developmental delays, exhaustion, decreased energy, feelings of worthlessness, overwhelming guilt, impaired thinking and concentration, lack of direction, and self-harm are all indicators of depressive disorders. (iv) The indicators must result in extreme anxiety or a lack of functioning; (iii) The indications do not meet the criteria for a mixed episode. (v) Chemicals, health issues, or bereavement shouldn't be linked to warning indications. [27

ISSN: 2582-7219 | www.ijmrset.com | Impact Factor: 8.206| ESTD Year: 2018|

International Journal of Multidisciplinary Research in Science, Engineering and Technology (IJMRSET)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

V. TREATMENT

Serotonergic/norepinephrinergic antidepressants

The Food and Drug Administration, or FDA, has approved many serotonin norepinephrine reuptake inhibitors (SNRIs) and selective serotonin reuptake inhibitors (SSRIs) for the treatment of SAD, GAD, and Parkinson's disease. Regardless of these classifications, medications that are not approved for a particular condition are commonly administered "off-label" in medical settings. It has been shown that first-line treatments for PD, GAD, and SAD, as well as selective serotonin reuptake inhibitors (SNRIs), are successful in treating anxiety-related conditions. According to a recent meta-analysis, the majority of SSRIs and SNRIs are superior than placebo in the treatment of GAD, with duloxetine and escitalopram perhaps having the largest effect sizes. The recommended course of treatment can be anywhere from three to six months to one to two years or more. Even though Although there is minimal proof that long-term SSRI or SNRI use has detrimental effects, tachyphylaxis is a concern. Additionally, these medications are frequently well taken, with only mild adverse effects like headaches, constipation, diarrhea, dry mouth, and lightheadedness.[28]

Mixed Antidepressants

Presynaptic antagonism is one of the many pharmacological effects of mirtazapine. Compared to SSRIs and SNRIs, its benefits include better appetite and sleep, more safety for elderly patients, fewer drug interactions, and a lower chance of sexual side effects. Among the adverse effects of antihistamines are dry mouth, sleepiness, and weight gain. Clinical trials assessing mirtazapine for diseases related to anxiety are extremely rare.[28]

A dopaminergic norepinephrine reuptake inhibitor, bupropion is approved for use in treating MDD, ADHD, and quitting smoking. There has been limited research on bupropion as a stand-alone treatment for stress, despite the fact that it has been used as an adjuvant to reduce sexual side effects in people with anxiety who are on SSRIs.[28]

The sole drug approved by the FDA for mental illnesses is nefazodone, a serotoninergic-modifying antidepressant that is anticipated to block postsynaptic 5-HT2 receptors and obstruct 5-HT reuptake.[28]

Gamma aminobutyric acid (GABA)

Benzodiazepines: Prior to SSRIs, benzodiazepines were used as first-line treatments for stress in medical settings. However, there are concerns about geriatric falls and the possibility of tolerance, dependence, overuse, or misuse. However, for short-term use and possibly more than eight weeks of therapy, there is minimal evidence that SSRIs and other first-line treatments are better than or more well tolerated than benzodiazepines for anxiety-related disorders, especially GAD. For qualified patients who have not reacted to or tolerated many SRI and buspirone trials,[28] BZDs may be used to treat generalized anxiety disorder. Through allosteric modulation of the GABA receptor, they enhance the endogenous GABA's CNS inhibitory effects. Due to concerns about tolerance and dependence, as well as a lack of proven efficacy for treating concurrent depression, the majority of specialists have recommended against long-term use of BZDs since SRIs were initially prescribed as first-line therapies.[29]

Anticonvulsants

The FDA has approved anticonvulsants to treat seizures, fibromyalgia, and neuronal pain. Numerous trials have demonstrated the efficacy and tolerability of pregabalin in the treatment of generalized anxiety disorder [29]. Pregabalin's studies have led to the suggestion that gabapentin, an earlier GABA analog with the same structure and mode of action, could also help treat generalized anxiety disorder symptoms.[29]

Tricyclic Antidepressants (TCA)

The class of drugs known as tricyclic antidepressants (TCAs) is mostly used as an antidepressant. [30] Early in the 1950s, TCAs were found, and later that year, they were put on the market. [31] Their chemical structure, which consists of three rings of atoms, gives them their name. Four rings of atoms make up the closely related class of antidepressant drugs known as tetracyclic antidepressants (Teca's).

Even though TCAs are occasionally prescribed for depressive disorders, newer antidepressants like selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), and norepinephrine reuptake inhibitors (NRIs) have largely replaced them in clinical use in most parts of the world. TCAs and SSRIs have been reported to have comparable levels of side effects.[32]

ISSN: 2582-7219 | www.ijmrset.com | Impact Factor: 8.206| ESTD Year: 2018|

International Journal of Multidisciplinary Research in Science, Engineering and Technology (IJMRSET)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

By inhibiting the serotonin transporter (SERT) and the norepinephrine transporter (NET), most TCAs function primarily as SNRIs. This raises the synaptic concentrations of these neurotransmitters and, consequently, increases neurotransmission. [33] [34] Notably, the TCAs are not very effective as dopamine reuptake inhibitors (DRIs) because, with the exception of amineptine, they have a weak affinity for the dopamine transporter (DAT). [33] Serotonin and norepinephrine have both been strongly linked to anxiety and depression, and it has been demonstrated that promoting their activity can help with these mental illnesses. [35]

Antihistamines

RCTs that are double-blind and include active comparators and a placebo such as buspirone or BZDs, have backed the histamine-blocking medication hydroxyzine and demonstrated its efficacy. like these tried-and-true treatments for generalized anxiety disorder. The trials indicate that the usual daily dosage is 50 mg, taken twice or three times day, and that the most frequent adverse effect is sleepiness.[36]

VI. CONCLUSION

The effectiveness of mental health treatments can be evaluated nationally. Most persons who are suspected of having an anxiety or depressive disorder do not receive the appropriate care. Conditions linked to anxiety and depression are common, and they significantly impact productivity and quality of life. Cognitive-behavioral therapy, interpersonal psychotherapies, and antidepressant medications are some of the most effective treatments for depression, as per national guidelines for treatment. 1–5 Evidence supports the effectiveness of dysthymia treatments, notwithstanding the paucity of material currently accessible on the subject . Children and teenagers frequently suffer from anxiety-related disorders, which can seriously impair their everyday functioning and frequently result in psychological avoidance that interferes with developmental tasks. Although they lack data and pose additional risks, other treatment options such tricyclic antidepressant drugs and the impending use of benzodiazepines may be considered. Current studies on humans and animals proves that anxiety -related diseases are associated with changes in the structure and function of neurons, and these neurological abnormalities can be improved in a number of ways by effective therapies using medications or psychoanalysis. Psychiatry has been searching for innovative pharmaceutical drugs specifically made to treat anxiety problems for decades. However, the discipline is gradually advancing thanks to thorough study into efficiently treating anxiety with medications that were previously permitted for other conditions. I reviewed the substantial body of data on pharmacological treatment of primary anxiety disorders in this review, updating it to incorporate the most recent findings allowing off-label use of drug groups such anticonvulsants, novel depression medicines, and the second - generation antipsychotic medications

REFERENCES

1. Key substance use and mental health indicators in the United States: results from the 2019 National Survey on Drug Use and Health

2.Garakani A., Murrough J.W., Freire R.C., et al. Pharmacotherapy of anxiety disorders: current and emerging treatment options. Front Psychiatry. 2020;11 doi: 10.3389/fpsyt.2020.595584.

3. American Psychiatric Association . American Psychiatric Publishing; 2013. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th ed.

4. Adjaye-Gbewonyo D., Boersma P. Early release of selected estimates based on data from the 2021 National Health Interview Survey. National Center for Health Statistics. https://www.cdc.gov/nchs/data/nhis/earlyrelease/earlyrelease202204.pdf Published April, 2022.

5. Kessler R.C., Sampson N.A., Berglund P., et al. Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys. Epidemiol Psychiatr Sci. 2015;24(3):210–226. doi: 10.1017/S2045796015000189.

6. Spitzer R.L., Kroenke K., Williams J.B., Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–1097. doi: 10.1001/archinte.166.10.109254.

7. Kessler R.C., Wang P.S. The descriptive epidemiology of commonly occurring mental disorders in the United States. Annu Rev Public Health. 2008;29:115–129. doi: 10.1146/annurev.publhealth.29.020907.090847.

8. Yonkers K.A., Warshaw M.G., Massion A.O., Keller M.B. Phenomenology and course of generalised anxiety disorder. Br J Psychiatry. 1996;168(3):308–313. doi: 10.1192/bjp.168.3.308.

9. Yonkers K.A., Dyck I.R., Warshaw M., Keller M.B. Factors predicting the clinical course of generalised anxiety disorder. Br J Psychiatry. 2000;176:544–549. doi: 10.1192/bjp.176.6.544.

ISSN: 2582-7219 | www.ijmrset.com | Impact Factor: 8.206| ESTD Year: 2018|

International Journal of Multidisciplinary Research in Science, Engineering and Technology (IJMRSET)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

10. Fava M., Rush A.J., Alpert J.E., et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR∗D report. Am J Psychiatry. 2008;165(3):342–351. doi: 10.1176/appi.ajp.2007.06111868.
11. Rodriguez B.F., Weisberg R.B., Pagano M.E., et al. Characteristics and predictors of full and partial recovery from generalized anxiety disorder in primary care patients. J Nerv Ment Dis. 2006;194(2):91–97. doi: 10.1097/01.nmd.0000198140.02154.32.
12. Strawn J.R., Geracioti L., Rajdev N., Clemenza K., Levine A. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert Opin Pharmacother. 2018;19(10):1057–1070. doi: 10.1080/14656566.2018.1491966.
13. Garakani A., Murrough J.W., Freire R.C., et al. Pharmacotherapy of anxiety disorders: current and emerging treatment options. Front Psychiatry. 2020;11 doi: 10.3389/fpsyt.2020.595584.
14. He H., Xiang Y., Gao F., et al. Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: a network meta-analysis. J Psychiatr Res. 2019;118:21–30. doi: 10.1016/j.jpsychires.2019.08.009.
15. Buppert C. The perils of off-label prescribing. J Nurs Pract. 2012;8(7):567–568.
16. Stahl S.M. Cambridge University Press; 2021. Stahl's Essential Psychopharmacology: The Prescriber's Guide. 7th ed.
17. Cassano G.B., Baldini Rossi N., Pini S. Psychopharmacology of anxiety disorders. Dialogues Clin Neurosci. 2002;4(3):271–285. doi: 10.31887/DCNS.2002.4.3/gcassano.
18. Baldwin D.S., Anderson I.M., Nutt D.J., et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403–439. doi: 10.1177/0269881114525674.
19. Stahl S.M. Cambridge University Press; 2021. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 5th ed.
20. Food and Drug Administration FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class Published September 23, 2020.
21. Slee A., Nazareth I., Bondaronek P., Liu Y., Cheng Z., Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. [published correction appears in Lancet. 2019;393(10182):1698]
22. Hirschtritt M.E., Olfson M., Kroenke K. Balancing the risks and benefits of benzodiazepines. JAMA. 2021;325(4):347–348. doi: 10.1001/jama.2020.22106.
23. Siu A.L., the US Preventive Services Task Force Screening for depression in adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2016;315(4):380–387. doi: 10.1001/jama.2015.18392.
24. Health Resources and Services Administration Shortage https://data.hrsa.gov/topics/health-workforce/shortage-areas Published September 29, 2021.
25. Brown M., Moore C.A., MacGregor J., Lucey J.R. Primary care and mental health: overview of integrated care models. J Nurs Pract. 2021;17(1):10–14. doi: 10.1016/j.nurpra.2020.07.005.
26. Melaragno AJ. Pharmacotherapy for anxiety disorders: from first-line options to treatment resistance. Focus.2021;19(2):145-160.https://doi.org/10.1176/appi.focus.20200048
27. Ströhle A. Physical activity, exercise, depression and anxiety disorders. J Neural Transm. 2009;116:777-784.
28. Benazzi F. Various forms of depression. Dialogues Clin. Neurosci. 2006;8(2):151-161.https://doi.org/10.31887/DCNS.2006.8.2/fbenazzi
29. Young AS, Klap R, Sherbourne CD, Wells KB.The Quality of Care for Depressive and Anxiety Disorders in the United States. Arch Gen Psychiatry.2001;58(1):55–61. DOI:10.1001/archpsyc.58.1.55
30. Moraczewski J, Awosika AO, Aedma KK (2025). "Tricyclic Antidepressants". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 32491723. Retrieved 24 May 2025.
31. Carson VB (2000). Mental health nursing: the nurse-patient journey W.B. Saunders. ISBN 978-0-7216-8053-8. pp. 423
32. Trindade E, Menon D, Topfer LA, Coloma C (November 1998). "Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis". CMAJ. 159 (10): 1245–1252. PMC 1229819. PMID 9861221.
33. Tatsumi M, Groshan K, Blakely RD, Richelson E (December 1997). "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". European Journal of Pharmacology. 340 (2–3): 249–258. doi:10.1016/S0014-2999(97)01393-9. PMID 9537821

ISSN: 2582-7219 | www.ijmrset.com | Impact Factor: 8.206| ESTD Year: 2018|

International Journal of Multidisciplinary Research in Science, Engineering and Technology (IJMRSET)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

34. Gillman PK (July 2007). "Tricyclic antidepressant pharmacology and therapeutic drug interactions updated". British Journal of Pharmacology. 151 (6): 737–748. doi:10.1038/sj.bjp.0707253. PMC 2014120. PMID 17471183.

35. Rénéric JP, Lucki I (March 1998). "Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test". Psychopharmacology. 136 (2): 190–197. doi:10.1007/s002130050555. PMID 9551776. S2CID 8093564.

36. Young AS, Klap R, Sherbourne CD, Wells KB.The Quality of Care for Depressive and Anxiety Disorders in the United States. Arch Gen Psychiatry.2001;58(1):55–61. DOI:10.1001/archpsyc.58.1.55

INTERNATIONAL STANDARD SERIAL NUMBER INDIA

INTERNATIONAL JOURNAL OF MULTIDISCIPLINARY RESEARCH

IN SCIENCE, ENGINEERING AND TECHNOLOGY

| Mobile No: +91-6381907438 | Whatsapp: +91-6381907438 | ijmrset@gmail.com |

www.ijmrset.com